Sir Mortimer Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
Location status: Recruiting
Recruiting
NCT Number: NCT02333110
GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible.
- Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation
- Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
- WHO performance status of 0-2
- Aged 18 years or older
- Ability to sign and understand an informed consent form
Exclusion criteria
- Potentially curable patient
- Previous palliative radiation with hypofractionation
- Tumor located near the spinal cord or in the brain
- Pregnant or nursing woman
Treatment and study plan
Spatially fractionated radiation therapy
RadiationA single dose of 15-20Gys of spatially fractionated radiation therapy
Other names: GRID radiation therapy
Primary outcomes
-
Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire
Time frame: 3 months post treatment
Secondary outcomes
-
Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)
Time frame: 1 week
-
Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0)
Time frame: 3, 6, 9, 12 months
-
Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response
Time frame: 3 months
-
Tumor response, measured on CT-scan
Time frame: 8 weeks
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Registry information
Official study title
Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Important dates
- Study start
- 2015
- Primary completion
- 2026
- Study completion
- 2027
- First posted
- Jan 7, 2015
- Registry last updated
- May 12, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.